Oral pharmacotherapy for the movement disorders of cerebral palsy.

about

Prospective open-label clinical trial of trihexyphenidyl in children with secondary dystonia due to cerebral palsy Anaesthesia and pain management in cerebral palsy.Clinical considerations in cerebral palsy and spasticity.

P2860

Q28240084-511C01F1-9FF4-452A-AE0D-F2F26B3218B5 Q33792386-0A666122-BE71-4C50-926C-D722C57DEC23 Q53495254-39B7D95C-21AB-4693-A1E8-5A6696ACF7F1

P2860

Oral pharmacotherapy for the movement disorders of cerebral palsy.

Item

http://www.wikidata.org/entity/Q41262347

description

1996 nî lūn-bûn

@nan

1996年の論文

@ja

1996年論文

@yue

1996年論文

@zh-hant

1996年論文

@zh-hk

1996年論文

@zh-mo

1996年論文

@zh-tw

1996年论文

@wuu

1996年论文

@zh

1996年论文

@zh-cn

name

Oral pharmacotherapy for the movement disorders of cerebral palsy.

@en

type

Item

label

Oral pharmacotherapy for the movement disorders of cerebral palsy.

@en

prefLabel

Oral pharmacotherapy for the movement disorders of cerebral palsy.

@en

P1476

Oral pharmacotherapy for the movement disorders of cerebral palsy.

@en

P2093

M R Pranzatelli

http://www.w3.org/2001/XMLSchema#string

P2860

Topical Review: Basal Ganglia: Functional Anatomy and Physiology. Part 1

The athetoid syndrome. A review of a personal series

7-Chlorokynurenic acid is a selective antagonist at the glycine modulatory site of the N-methyl-D-aspartate receptor complex

The functional anatomy of basal ganglia disorders

Primate models of movement disorders of basal ganglia origin

Dantrolene sodium: a review of its pharmacological properties and therapeutic efficacy in spasticity.

Tetrabenazine therapy of dystonia, chorea, tics, and other dyskinesias.

Biological profile of the metabolites and potential metabolites of the anticonvulsant remacemide.

Excitatory amino acids as a final common pathway for neurologic disorders.

Torsion dystonia: a double-blind, prospective trial of high-dosage trihexyphenidyl.

P304

S13-22

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/0883073896011001S03

http://www.w3.org/2001/XMLSchema#string

P478

11 Suppl 1

http://www.w3.org/2001/XMLSchema#string

P577

1996-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

8959457

http://www.w3.org/2001/XMLSchema#string

P921

pharmacotherapy

Oral pharmacotherapy for the movement disorders of cerebral palsy.

about

P2860

P2860

Oral pharmacotherapy for the movement disorders of cerebral palsy.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P698

P921